Clinical Trials Detail

Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive NSCLC

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR+ NSCLC

Objective
CategoryInformation
Study #:

S1403

Anatomic Site: Lung
Histology:
  • Non-Small Cell Lung Cancer (NSCLC)
  • Non-Small Cell Lung Carcinoma
Mutation:
  • EGFR exon 19 deletion
  • EFGR econ 21 (L858R) substitution
  • T790M mutation
Stage: NSCLC: Stage IV
Carcinoma: Recurring
Treatment Phase: Patients have histologically or cytologically confirmed stage IV or recurrent NSCLC and documented presence of mutation. Patients must not have received any prior systemic anticancer therapy.
Location:
Study Link: https://clinicaltrials.gov/ct2/show/NCT02438722?term=S1403&rank=1

Clinical Trial Categories

  • Lung